BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 19, 2001
 |  BioCentury  |  Product Development

The Enbrel space

It's no secret that Immunex Corp. can't make enough of its Enbrel etanercept rheumatoid arthritis drug to meet demand. With every passing day, there is the potential that new patients will start taking the one competing anti-TNF drug, Johnson & Johnson's Remicade anti-TNF chimeric monoclonal antibody, which is approved for both RA and Crohn's disease.

IMNX also faces the possibility that it won't have ramped up production before a third compound is approved in the TNF space: Abbott Laboratories' D2E7 human anti-TNF antibody. ABT, which gained rights to D2E7 from Cambridge Antibody (LSE:CAT; CATG) through its acquisition of Knoll Pharmaceuticals in the first quarter of this year, plans to submit a BLA to the FDA in the second quarter of 2002 and hopes for approval in...

Read the full 638 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >